JZT: Net profit in the third quarter was 7.758 million yuan, a decrease of 78.30%

JZT announced that the revenue for the third quarter was 363 million yuan, a year-on-year decrease of 5.51%; the net profit was 7.758 million yuan, a year-on-year decrease of 78.30%. The revenue for the first three quarters was 1.627 billion yuan, a year-on-year decrease of 21.13%; the net profit was 152 million yuan, a year-on-year decrease of 36.94%

JZT released its performance for the first half of the year, with a net profit attributable to the parent company of 144 million yuan, a year-on-year decrease of 29.71%

JZT released its semi-annual report for 2025, reporting operating income of 1.265 billion yuan, a year-on-year decrease of 24.71%; net profit attributable to shareholders of the parent company was 144 million yuan, a year-on-year decrease of 29.71%; net profit excluding non-recurring gains and losses was 136 million yuan, a year-on-year decrease of 28.45%; basic earnings per share were 0.1699 yuan

The concept of innovative drugs fluctuates and rebounds, JZT hits the limit up

The concept of innovative drugs has rebounded, with JZT hitting the daily limit, Hinova, RemeGen, and Shenzhou Cell rising over 10%, while Fuyuan Pharmaceutical, Kangchen Pharmaceutical, Guangshengtang, and Nuo Cheng Jianhua are among the top gainers

JZT's stock hit the upper limit and achieved a 2-day consecutive increase, with a cumulative rise of 21.0%

Innovative drug concept stocks rebound after hitting bottom, JZT reaches the daily limit

Innovative drug concept stocks rebound after hitting bottom, JZT reaches the daily limit, ClinPlus rises over 10%, Medicilon, SDKX, and Hengrui Pharma all rise